Rating Change
Wedbush analysts reiterated a Neutral rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) on July 10, 2026.
reiterateNASDAQ:NTLA
Wedbush Reiterates Neutral Rating on Intellia Therapeutics, Inc. (NTLA)
Rating Change Wedbush analysts reiterated a Neutral rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) on July 10, 2026. Market Context Intellia Therapeutics, Inc.
Market Context
Intellia Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $14.21 with a market capitalization of $1.0B.
Analyst coverage from Wedbush provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Intellia Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Intellia Therapeutics, Inc.
Among the 10 most recent ratings: 5 Buy, 4 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 10, 2026 | Wedbush | Neutral | N/A |
| Jun 16, 2026 | Canaccord Genuity | Buy | N/A |
| Jun 15, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 15, 2026 | Wedbush | Neutral | N/A |
| Jun 15, 2026 | Citizens | Market Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View NTLA Stock Page
Frequently Asked Questions
What does a Neutral rating mean for NTLA?
A Neutral rating from Wedbush reflects the analyst's outlook on Intellia Therapeutics, Inc. (NASDAQ:NTLA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the NTLA forecast page.